Final Program [International AIDS Society (11th: 1996: Vancouver, Canada)]

VENUE ROOM TRACK SESSION NO. TIME / SESSION PATHWAYS
A2 322 Track A: Basic Science
Room Abstract Session:
8/s15 Gene Therapy
Chairs:
Cloudio Brabazon, Canada / Eric Cohen, Canado
We.A.270 13:30
VIRION-TARGETED VIRAL INACTIVATION AGAINST HIV-I USING VPR CHIMERIC PROTEINS
Cohen, Eric A, Nie Z, Mercier J, Bergeron D, Pignac-Kobinger G. Laboratoire de Retrovirologie Humaine, Dep. de Microbiologie et
Immunologie, Universite de Montreal, Montreal, QC, Canada................................................................................................................................................................................................................................................
We.A.271 13:45
INHIBITION OF HIV-I REPLICATION IN ANTI HIV-I GENE EXPRESSING LONG TERM BONE MARROW CULTURES
ESTABLISHED FROM CD34+ CELLS OF HIV-I INFECTED DONORS
Bauer, GerhardI,Wen SFI, Bahner I', Kearns K', Zaia J2, Kohn DBi. IChildrens Hospital, Los Angeles; 2City of Hope Medical Center,
Duarte, CA, USA................................................................................................................................................................................................................................................
We.A.272 14:00
HEMATOPOIETIC STEM CELL THERAPY WITH A SIV-SPECIFIC RIBOZYME PROTECTS T CELLS AND MACROPHAGES
FROM SIV INFECTION
Johnson, R PaulI, Rosenzweig MI, Marks DFI, Heusch M2, Wong-Staal F2. INew England Regional Primate Research Center, Harvard
Medical School, Southborough, MA; 2Dept. of Medicine, University of California, San Diego, La Jolla, CA, USA................................................................................................................................................................................................................................................
We.A.273 14:15
RIBOZYME-BASED GENE THERAPY APPROACH FOR THE TREATMENT OF HIV-I INFECTION
Sun, Lun-Quan, Gerlach W, Symonds G. RW Johnson Pharmaceutical Research Institute, Sydney Australia................................................................................................................................................................................................................................................
We.A.274 14:30
IMPROVED ANTI-HIV EFFICACY OF RETROVIRAL GENE THERAPY VECTORS CARRYING A tat-RESPONSIVE PROMOTER
AND A CONSERVED HIV PACKAGING SIGNAL
Robinson, Deborah R, Chang, LJ. University of Alberta, Edmonton, AB, Canada.
ON
CY\...............................................................................................................................................................................................................................................
We.A.275 14:45
DEVELOPMENT OF NOVEL ANTI-HIV AGENTS THAT INTERFERE WITH A RIBOSOMAL FRAMESHIFTING EVENT
0
REQUIRED FORTHE PRODUCTION OF VIRAL ENZYMESU
CMelangon P', Payant CI,Yao XJ2, Cohen EA2, Brakier-Gingras, Lea2. Dep. de Biochimie et Microbiologie, Universite de Montrdal, >
Montreal, QC, Canada.
C
0
O
0)
U
C
0)
0)
C
0
C
0)
C

X

193